FANCD2 and autoimmune thrombocytopenic purpura: While in one patient with a FANCA mutation, the ITP started at 17 months of age and showed a chronically persisting course with severe purpura, that responded to IVIG and synthetic androgen therapy, the other patient (with FANCD2 mutations) had a self-limited course that resolved after a single administration of IVIG.